

AST- GOT LR

Use

Kit for measurement of aspartate-aminotransferase in serum or plasma - Kinetic UV optimized method IFCC*

* International Federation of Clinical Chemistry and Laboratory Medicine

Summary

AST measurements are used in the diagnosis and treatment of certain types of liver and heart disease. Principle

The enzyme aspartate-aminotransferase (AST) (or glutamic-oxaloacetic transaminase/GOT) catalyzes reaction between alpha-ketoglutarate and

L-aspartate giving glutamate and oxaloacetate. In presence of malate dehydrogenase (MDH), oxaloacetate reacts with NADH giving malate and NAD+. The rate of decrease of absorbance due to oxidation of NADH to NAD+ is directly proportional to sample AST activity.

Reagents

| R1 | Goods buffer pH 7.8 80.0 mmol/l | |
|----|---------------------------------|--|
| | L-aspartate 240.0 mmol/l | |
| | LDH ≥ 1800 U/I | |
| | MDH ≥ 800 U/I | |
| R2 | Goods buffer pH 7.8 80.0 mmol/l | |
| | alpha-ketoglutarate 65.0 mmol/l | |
| | NADH ≥ 1.18 mmol/l | |

Preparation of Reagents

The reagents are liquid and ready to use. For use as monoreagent (procedure "sample starter"), put the contents of R2 into R1. For smaller usage add to every 4 ml of reagent R1, 1 ml of reagent R2. Remove the reagents from refrigerator only as long as necessary for their use and recap them immediately.

Storage and Stability

Store the kit at 2-8°C.

- After opening, the vials R1 and R2 are stable 90 days if recapped immediately and protected from contamination, evaporation, direct light, and stored at the correct temperature.
- Working solution stability (R1+ R2): 20 days at 2-8°C.

Precaution in Use

The product is not classified as dangerous (DLg. N. 285 art. 28 l. n. 128/1998. The final concentration of the components is below the limits imposed by Regulation (EC) No. 1272/2008 - CLP (and amendments) and Directive subsequent 88/379/CEE and subsequent amendments to the classification-packaging and labeling of dangerous substances. However the reagent should be handled with care, according to good laboratory practice.

Caution: the reagents contain Sodium Azide (0.095%) as preservative. Avoid swallowing and contact with skin, eyes and mucous membranes. In case of contact with eves rinse immediately with plenty of water and seek medical advice.

Waste Management

Please refer to the local legal requirements. Speciments Collection and Preparation

Serum-heparinized plasma or EDTA plasma.

Do not use samples with haemolysis because this one could cause results wrongly positive. The

anticoagulants containing ammonium salt (es. ammonium heparinate) should not be used.

The AST activity tends to decrease (< 8%) after 3 days at 2-8°C.

Note

- The kit, according to this method, must be used in manual procedures. About automatic using follow specific applications.
- Avoid direct light, contamination and evaporation.
- The volumes in the procedure can be changed proportionally.

- In case of complaint or quality control request, refer to the lot number on the package or the lot number on the singles vials.

Procedures

| Wavelength | 340 (334-365) nm | |
|--|----------------------|--|
| Working temperature | 37°C | |
| Optical path | 1 cm | |
| Reaction | kinetic (decreasing) | |
| Bring the reagents at 15-25°C before using them. | | |

- Monoreagent Procedure"sample starter"

| • | |
|---------------|---|
| BLANK | SAMPLE |
| 1000 µl | 1000 µl |
| 100 µl | |
| | 100 µl |
| 1' a 37°C. Me | easure the absorbance of |
| 0 and after | 1, 2, 3 minutes. Then, |
| ance variatio | on $\Delta E/min$ obtained by |
| | |
| | BLANK 1000 μl 100 μl 1' a 37°C. Me 0 and after ance variatio |

- Bireagent Procedure "substrate starter"

| | BLANK | SAMPLE | | |
|------------------------|-----------------|----------------|------------|----|
| Reagent R1 | 800 µl | 800 µl | | |
| Distilled water | 100 µl | | | |
| Sample | | 100 µl | | |
| Mix, incubate at 37° | C for 1' And th | en add: Re | agent R | 2 |
| 200 µl 200 | μl | | | |
| Mix, then incubate for | ° 1' a 37°C. Me | easure the abs | orbance of | b |
| sample (EC) at time | e 0 and after | 1, 2, 3 minu | tes. Ther | ١, |
| calculate the absor | bance variatio | n ∆E/min ob | otained b | y |
| performed readings. | | | | |

Calculation

| AST [] | 1/11 = | ∆F/min | x | 1746 | |
|--------|--------|--------|---|------|--|
| | //11 = | | • | 1/40 | |

The factor and the reagent performances are related to 37°C , 1 cm and 340 nm.

Reference Values to 37°C

| Serum – plasma | [U/I] 37°C | |
|----------------|------------|--|
| Women ≤ | 31 [U/I] | |
| Men ≤ | 37 [U/I] | |

Reference values are considered indicative since each laboratory should establish references ranges for its own patient population. The analytical results should be evaluated with other information coming from patient's clinical history.

ANALYTICAL PERFORMANCES

Linearity

Reaction is linear up to a concentration of 400 U/I. Samples with values exceeding this range must be diluted with saline solution. Multiply, then, the result for diluting factor.

REF 3700650 6x50 ml 3701230 12x30 ml

CEIVD For in vitro medical device Analytical sensitivity

The test sensitivity in terms of detection limit is 2.4 11/1

"Intra-Assay" precision (within-Run)

| Determined on 20 sam | ples for eacl | n control (N-H) |
|-------------------------|---------------|------------------|
| (Normal-High). Results | : | |
| MEAN (U/I) | N = 39.70 | H = 130.35 |
| D.S. | N = 1.45 | H = 2.17. |
| C.V.% | N = 3.66 | H = 1.67 |
| "Inter-Assay" precision | on (betweer | n-run) |
| Determined on 20 sam | ples for eac | h control (N-H). |
| Results: | • | . , |
| MEAN (II/I) | N = 41.32 | H= 131 63 |

| | N = 41.5Z | 11-131.0 |
|-------|-----------|----------|
| D.S. | N = 1.34 | H = 2.17 |
| C.V.% | N = 3.25 | H = 1.63 |
| | | |

Correlation

A study based comparing this method with a similar method on 20 samples has given a correlating factor r = 0.99

y = 0.9227x + 1.399

| Interferences | | |
|-----------------------|-------------|---------------------|
| No interference was o | observed b | y the presence of : |
| Triglycerides | ≤ 1000 | mg/dl |
| Bilirubin | ≤ 30 | mg/dl |
| Ascorbic acid | ≤ 25 | mg/dl |
| Hemoglobin interfere | s also at m | inimum |
| concentrations. | | |

Quality Controls

It's necessary, each time the kit is used, to make the quality controls and to check that values obtained are within the acceptance range provided in the insert. Each laboratory should estabilish its own mean and standard deviation and adopt a quality control program to monitor laboratory testing. Bibliography

Karmen A. et al.: J. Clin. Invest. 34, 126 (1955). Young DS, Pestaner LC and Gibberman V: Clin. Chem., 21(5),1D-432D (1975).

Lorentz K, Röhle G, Siekmann L:. DG Klinische Chemie Mitteilungen, 26, 190 (1995).

Bergmeyer HU, Horder M, Rej R.: International Federation of Clinical Chemistry (IFCC) Scientific Committee. J. Clin. Chem. Clin. Biochem., 24, 497 (1986)

Kaplan LA, Pesce AJ: "Clinical Chemistry", Mosby Ed. (1996).

Symbols

- CE CE Mark (requirement of 98/79 regulation) IVD in vitro medical device LOT Batch Code 2 Use by X Storage temperature limits li Read instruction for use Gesan Production srl 怸 Shelter from sunlight UDI Unique Identified Number
- Production data